University of Chicago

CancerVAX CEO Ryan Davies Discusses Cancer Drug Development with Dr. Ezra Cohen

Retrieved on: 
Thursday, November 2, 2023
Attention, Moores Cancer Center, CancerVax, San Diego, University, Medicine, University of Chicago, Cancer, Patient, Associate, Pharmaceutical industry, LEHI

LEHI, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago.

Key Points: 
  • LEHI, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago.
  • “I got into medicine to make a difference in people’s lives, said Dr. Cohen.
  • “I realized that cancer patients needed more focus and more attention than other patient groups.
  • Cohen is a lovely man with incredible experience and noble intentions,” said CancerVax CEO, Ryan Davies.

CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101, A NOVEL CDH17 CAR T CELL THERAPY FOR ADVANCED GASTROINTESTINAL CANCERS

Retrieved on: 
Tuesday, October 31, 2023
ASX, Stomach, FDA, CAR, Metastasis, CDH17, IND, Food, Gastrointestinal cancer, University, Doctor of Philosophy, Penns, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Glomus tumor, Nature Cancer, Colorectal cancer, Clinical trial, Perelman School of Medicine at the University of Pennsylvania, University of Chicago, Immunotherapy, Cancer, Patient, Toxicity, Neoplasm, CHM, Investigational New Drug, Pharmaceutical industry, Medical imaging, Chimera, MD, Medicine

FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy

Key Points: 
  • FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy
    Phase 1A clinical trial will enroll patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours
    SYDNEY, Oct. 31, 2023 /PRNewswire/ -- Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers.
  • The company plans to investigate CHM 2101 in a multi center, open label Phase 1A/B clinical trial for patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.
  • CHM 2101 is a 3rd generation, novel CDH17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.
  • With the FDA IND clearance Chimeric will now begin the initiation of a phase 1 /2 multi-site clinical trial in patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.

Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO

Retrieved on: 
Friday, October 27, 2023
Bank, Therapy, University of Chicago, UBS, HEC Paris, SVB Securities, Head, Alcon, Retina, Marketing, Latin honors, AMD, Organization, Acquisition, Eye, Lead, University, Health, Patient, Sports Medicine Australia, Rejuvenation, BofA Securities, University of Rouen Normandy, Growth, Business administration, Paris, Doctor of Pharmacy, Master of Business Administration, Pharmaceutical industry, Presbyopia, HSBC, Country, Biology, ABPI, Medicine, R, The arts, University of Chicago Booth School of Business, School, CFO, Management, Ophthalmology, Novartis, Aerie, Business

MELBOURNE, Australia, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that the company’s Chief Executive Officer, Dr. Megan Baldwin, will transition to Founder and Chief Innovation Officer, effective today, reflective of the company’s strategy to advance its US and global presence and commercialization strategy for sozinibercept (OPT-302).

Key Points: 
  • Concurrently, Opthea is pleased to announce the appointments of U.S.-based executives, Dr. Frederic Guerard as Chief Executive Officer and Peter Lang as Chief Financial Officer.
  • “On behalf of the Board, I am pleased to welcome Fred Guerard and Peter Lang to Opthea’s leadership team.
  • Both come to Opthea with impressive credentials to position Opthea for future growth and success,” commented Dr. Jeremy Levin, Chairman of Opthea’s Board of Directors.
  • Peter graduated with a Master of Business Administration from The University of Chicago, Booth School of Business, with High Honors.

Borr Drilling Limited - Appointment of Directors to the Board

Retrieved on: 
Tuesday, October 17, 2023
Retirement, NYSE, Advisory board, Resource and Energy Economics, Doctor of Philosophy, University of Chicago, European, Government, Partner, University, Goldman Sachs, Research, Energy policy, Pritzker School of Molecular Engineering at the University of Chicago, Energy Policy Institute of Australia, Commodity, BORR, Management, Economics

HAMILTON, Bermuda, Oct. 17, 2023 /PRNewswire/ -- Borr Drilling Limited (the "Company") (OSE: BORR) and (NYSE: BORR) today announced that Mr. Jeffery Currie and Mr. Patrick Schorn have been appointed as Directors of the Company by the Board with effect from 16 October 2023.

Key Points: 
  • HAMILTON, Bermuda, Oct. 17, 2023 /PRNewswire/ -- Borr Drilling Limited (the "Company") (OSE: BORR) and (NYSE: BORR) today announced that Mr. Jeffery Currie and Mr. Patrick Schorn have been appointed as Directors of the Company by the Board with effect from 16 October 2023.
  • Since his retirement, Jeff has joined the board of Abaxx Technologies and The University of Chicago's Energy Policy Institute where he serves as the Chairman of the Advisory Board.
  • Borr Drilling, a company I have known for years, can do this at scale with low costs.
  • Mr. Schorn became CEO of Borr Drilling in September 2020, after serving as a Director of the Board since January 2018.

STAT to host fifth annual flagship STAT Summit

Retrieved on: 
Tuesday, October 10, 2023
Parkinson's disease, Eli Lilly and Company, Health, Michael J. Lenardo, State room, Interest, St. Jude Children's Research Hospital, GSK, The Michael J. Fox Foundation, Death, Summit, University of Washington, STAT, University, Medicine, Hospital, Dana–Farber Cancer Institute, Disease, Eli Lilly, Emergency medicine, James R. Downing, Biogen, Science, Priscilla, Violence, University of Chicago Medical Center, Patient, HMS, University of Chicago, Pharmaceutical industry, Management, Nursing

BOSTON, Oct. 10, 2023 /PRNewswire/ -- STAT, the leading media company reporting on health, science, and medicine, is set to host its fifth annual flagship event, the 2023 STAT Summit, later this month. The hybrid event will take place on October 18-19, 2023, at the State Room in Boston, with programming beginning at 9:00 a.m. ET each day. The Summit will feature frank conversations on vital topics with C-suite industry leaders, and spirited discussions with leading academics and patient advocates on the biggest challenges across health care today.

Key Points: 
  • 2023 STAT Summit will feature leading executives from Eli Lilly, Biogen, GSK, and more, with virtual appearances from Michael J.
  • Fox, Mark Zuckerberg and Priscilla Chan
    BOSTON, Oct. 10, 2023 /PRNewswire/ -- STAT , the leading media company reporting on health, science, and medicine, is set to host its fifth annual flagship event, the 2023 STAT Summit , later this month.
  • The 2023 STAT Summit is presented by St. Jude Children's Research Hospital, and will feature a discussion with James R. Downing, M.D., St. Jude Children's Research Hospital president and CEO.
  • Top executives, key scientists, economists and health outcomes researchers will take the Summit stage to explore solutions together.

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Retrieved on: 
Tuesday, October 3, 2023
KRAS, STAT3, IRS, University, PD, Signal, Survival, RECIST, SCCHN, Pharmacokinetics, Immunotherapy, Cetuximab, Drug resistance, M.D, Patient, EGFR, Colorectal cancer, Escape Room, Neoplasm, Infrared spectroscopy correlation table, Tumor microenvironment, Safety, Disease, University of Chicago, Pharmaceutical industry

No dose-limiting toxicities (DLTs) were reported in either cohort and NT219 was well tolerated as a monotherapy and in combination with cetuximab.

Key Points: 
  • No dose-limiting toxicities (DLTs) were reported in either cohort and NT219 was well tolerated as a monotherapy and in combination with cetuximab.
  • Other results from the Phase 1/2 study will be provided at one of the upcoming medical conferences.
  • The Company is in the process of designing a Phase 2 study of NT219 in combination with cetuximab in 2L R/M SCCHN.
  • Gil Efron, Purple Biotech CEO, added, “I am very satisfied with the observed activity of NT219 in recurrent and/or metastatic SCCHN patients.

Procaps Group to Host Webinar on Colombian Pharma Market

Retrieved on: 
Monday, October 2, 2023
Pharmaceutical, Health, Medical Supplies, 1888 Chicago University club football team, Diversified Pharmaceutical Services, ANDI, University of Chicago, Universidad de los Andes, Specialization, Pharmaceutical industry, Harvard University, Management

Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced that it will host a webinar dedicated to the Colombian pharma market and its regulations on October 10th.

Key Points: 
  • Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced that it will host a webinar dedicated to the Colombian pharma market and its regulations on October 10th.
  • The Company will host a webinar at 10:00 a.m. Eastern time with Mariana Sarasti, Director of Pharmaceutical Industry Chamber within the National Business Association of Colombia (ANDI).
  • She has extensive experience in business development and strategy, as well as in project planning and management in the public and private sectors.
  • To access the webinar, please use the following information:

IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City

Retrieved on: 
Tuesday, September 26, 2023
Abstract, Graft-versus-host disease, KOL, University of Chicago, Society, University, ASH, SITC, SNO, Immunotherapy, Pakistan Society of Neuro-Oncology, Transplant, Development, Mixed-phenotype acute leukemia, Johns Hopkins School of Medicine, Leukemia, Webcast, Society for Immunotherapy of Cancer, Conference, Pharmaceutical industry

ET and will be accessible both virtually and in-person in New York, NY.

Key Points: 
  • ET and will be accessible both virtually and in-person in New York, NY.
  • The webcast will also be available under the “Events and Presentations” section of the Company’s website at https://investors.in8bio.com .
  • The event will offer the opportunity to gain Key Opinion Leader (KOL) insights into IN8bio’s clinical and scientific programs along with upcoming catalysts.
  • Following the live event, an archived replay of the webcast will be made available on our website.

HP Inc. Names David Meline to Board of Directors

Retrieved on: 
Thursday, September 21, 2023
Los Angeles Philharmonic, University of Chicago, PALO, HPQ, Amgen, 3M, Mechanical engineering, ABB, General Motors, Iowa State University, Mechanical, Business administration, Motion, University, HP Inc., London, Growth, NYSE, London School of Economics, Moderna, Pharmaceutical industry, Management, Economics

PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) today announced the appointment of David Meline to its Board of Directors.

Key Points: 
  • PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) today announced the appointment of David Meline to its Board of Directors.
  • “David has been instrumental in driving the growth and transformation of major global companies over the course of his four decades long career,” said Chip Bergh, Chair of HP’s Board of Directors.
  • “We are delighted to welcome David to HP’s Board of Directors,” says HP Inc. President and CEO, Enrique Lores.
  • The HP Board of Directors is one of the most diverse of any technology company in the U.S.

Abaxx Technologies Announces Additional Director to be Appointed Ahead of AGM

Retrieved on: 
Tuesday, September 19, 2023
University of Chicago, University, EPIC, EST, Doctor of Philosophy, Forecasting, Central Waqf Council, Energy Policy Institute of Australia, Goldman Sachs, Retirement, Partner, Podcast, Government, Research, Resource and Energy Economics, News, NEO, Management, Clearing house, Economics

TORONTO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Abaxx Technologies Inc., (NEO:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of the Abaxx Commodity Exchange and Clearinghouse (“Abaxx Singapore”), and producer of the SmarterMarkets™ Podcast, announces that effective October 2nd, economist and commodities strategist, Dr. Jeff Currie will join Abaxx as an independent member of its Board of Directors.

Key Points: 
  • Dr. Currie began his career teaching undergraduate and graduate level courses in microeconomics and econometrics at The University of Chicago and served as the associate editor of Resource and Energy Economics.
  • He recently announced his retirement as a Partner at Goldman Sachs, serving as Global Head of Commodity Research and Strategy.
  • Abaxx also announces that its Annual and Special Meetings of Shareholders will be held on November 16th 2023, at 1:00 p.m. Eastern Standard Time Zone (EST).
  • Dial-in details and an information circular will be mailed to registered shareholders ahead of the meeting.